Sort by 'likes'
Advances in Parkinson’s Disease Management
Parkinson's disease is a neurological disorder that affects the ability of a person to control body movements. It is caused by loss of nerve cells in the region of the brain that produces the neurotransmitter dopamine. Dopamine, the messenger between…
What’s New in Multiple Myeloma Management?
Multiple myeloma is diagnosed in over 100,000 patients each year worldwide. The FDA recently granted accelerated approval to Teclistamab, the first bispecific B-cell maturation (BCMA)-directed CD3 T-cell engager. The therapeutic armamentarium for myeloma now includes alkylating agents, corticosteroids, deacetylase inhibitors,…
Schizophrenia – Exploring Early Diagnosis and Treatment Options
Schizophrenia is one of the top 15 leading causes of disability throughout the world. It is a mental illness characterized by alterations to people’s thought and behavior which can include psychosis - a condition which makes it difficult for them…
Myeloma: 2016 Year in Review and Outlook for 2017
The treatment options for myeloma continued to evolve in 2016 with new agents, immune based therapies and repurposing of existing approved agents. High-dose therapy and autologous stem cell transplantation remain the backbone of upfront treatment in myeloma. We are talking…
Multiple Myeloma Stem Cells and Drug Resistance in Myeloma Management
Multiple myeloma is a heterogenous plasma cell disorder that contains a small fraction of clonogenic stem cells, just like many other cancers. Although the exact nature and biological properties of these cells remain elusive, multiple myeloma stem cells (MMSCs) have…